Entropy Neurodynamics Limited (ENP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Entropy Neurodynamics Limited (ENP) has a cash flow conversion efficiency ratio of -0.459x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.74 Million ≈ $-1.94 Million USD) by net assets (AU$5.96 Million ≈ $4.22 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Entropy Neurodynamics Limited - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how Entropy Neurodynamics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Entropy Neurodynamics Limited balance sheet liabilities for a breakdown of total debt and financial obligations.
Entropy Neurodynamics Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Entropy Neurodynamics Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Lite Strategy, Inc.
NASDAQ:LITS
|
-0.040x |
|
Demire Deutsche Mittelstand Real Estate AG
F:DMRE
|
0.053x |
|
TWL Holdings Bhd
KLSE:7079
|
-0.025x |
|
Minehub Technologies Inc
V:MHUB
|
-1.632x |
|
Bayview Acquisition Corp Class A Ordinary Shares
NASDAQ:BAYA
|
-0.001x |
|
Firetrade Engineering PCL
BK:FTE
|
0.045x |
|
Namuga Co. Ltd
KQ:190510
|
0.111x |
|
Abnova Taiwan Corp
TW:4133
|
0.003x |
Annual Cash Flow Conversion Efficiency for Entropy Neurodynamics Limited (2018–2025)
The table below shows the annual cash flow conversion efficiency of Entropy Neurodynamics Limited from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see ENP company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$5.96 Million ≈ $4.22 Million |
AU$-7.77 Million ≈ $-5.50 Million |
-1.303x | -22.03% |
| 2024-06-30 | AU$5.62 Million ≈ $3.98 Million |
AU$-6.00 Million ≈ $-4.25 Million |
-1.068x | -9.44% |
| 2023-06-30 | AU$4.13 Million ≈ $2.92 Million |
AU$-4.03 Million ≈ $-2.85 Million |
-0.975x | +0.01% |
| 2022-06-30 | AU$8.81 Million ≈ $6.23 Million |
AU$-8.59 Million ≈ $-6.08 Million |
-0.976x | -133.39% |
| 2021-06-30 | AU$18.87 Million ≈ $13.35 Million |
AU$-7.89 Million ≈ $-5.58 Million |
-0.418x | +68.78% |
| 2020-06-30 | AU$5.02 Million ≈ $3.55 Million |
AU$-6.72 Million ≈ $-4.75 Million |
-1.339x | -213.81% |
| 2019-06-30 | AU$5.12 Million ≈ $3.62 Million |
AU$-2.18 Million ≈ $-1.55 Million |
-0.427x | -103.30% |
| 2018-06-30 | AU$-7.27K ≈ $-5.14K |
AU$-93.93K ≈ $-66.46K |
12.924x | -- |
About Entropy Neurodynamics Limited
Entropy Neurodynamics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company's lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 … Read more